Diabetes Can Be Cured!

• ARTICLES
• DIET
• SYMPTOMS
• RECOGNITION
• TESTIMONIAL

Journal Published Clinically Tested Its Effectiveness!

The Clinical Test has been published in Journal Metabolism Clinical & Experimental Vol. 55 (2006) Pg. 923-927

Title: The influence of chromium chloride–containing milk to glycemic control of patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled trial.

This eminent journal is regarded by Dee Pei, Chang-Hsun Hsieh, Yi-Jen Hung, Jer-Chuang Li, Chien-Hsing Lee and Shi-Wen Kuo, the clinicians and researchers alike as an authoritative source of practical information on metabolic processes and diseases in the areas of nutrition, genetics, dystrophies, diabetes and gout. Reviews and surveys on the status of research and practice in specific metabolic disorders are featured. The aim of this study is to evaluate the effect and safety of chromium-containing milk powder in patients with type 2 diabetes mellitus.

A randomized, double-blind, placebo-controlled trial was conducted in Taiwan . A total of 60 patients with type 2 diabetes mellitus, aged 30 to 75 years, and on a dose of gliclazide sulfonylurea agent (V160 mg/d) for at least 3 months were enrolled. Their glycosylated hemoglobin ranged from 7.5% to 12%, fasting plasma glucose (FPG) from 140 to 250 mg/dL, and body mass index from 20 to 35 kg/m2.

The subjects were divided into 2 groups, one group to receive chromium-containing milk powder (chromium 200 lg/20 g milk powder) and the other to receive placebo twice a day for 16 weeks. Frequently sampled intravenous glucose tolerance test (IVGTT) was performed before and after treatment.

The chromium group demonstrated a lower FPG and fasting insulin (_38.1 F 9.2 vs 63 F 8. 5 mg/dL and _1.7 F 0.2 vs 1.9 F 0.3 lU/mL, respectively; P b .05), especially in male patients (_41 F 9.2 vs 85 F 11.7 mg/dL and _2.7 F 0.2 vs 3.1 F 0.3 lU/mL, respectively; P b .01), at the end of the study. Lower glycosylated hemoglobin was observed in chromium-treated male patients (_1.1 F 0. 5 vs 0.7 F 0. 2; P b .05). However, there were no significant changes in other metabolic parameters (lipid profiles including total cholesterol, triglyceride, low-density lipoprotein cholesterol, and high-density lipoprotein cholesterol), except improvement of insulin resistance (homeostasis model assessment for insulin resistance and insulin sensitivity index from frequently sampled intravenous glucose tolerancetest) observed in male patients (_2.1 F 1.1 vs _0.41 F 1.12 and 0.18 F 0.11 vs _0.15 F 0. 2, respectively; P b .05).

There were no adverse events in both groups, except for mild complaints in the chromium group on constipation (5%) and flatulence (5%). Intake of milk powder containing 400 lg/d of chromium for 16 weeks in subjects with type 2 diabetes mellitus resulted in lowering of FPG, fasting insulin, and improvement of metabolic control in male patients.

For viewing full contents, visit: www.elsevier.com/locate/metabol OR email to : ppmshah@gmail.com to get full copy.